BioCentury
ARTICLE | Emerging Company Profile

Tumor cell checkpoints

iOmx is discovering checkpoints that may work where PD-1/L1 doesn’t

December 9, 2016 2:10 AM UTC

iOmx Therapeutics AG is taking a systematic approach to identifying targets located on tumors that modify T cell activation. The resulting targets are complementary to but independent of PD-1/PD-L1 signaling, which may provide a way to treat patients who don’t respond to PD-1/PD-L1 inhibitors.

The company is starting with more than 20 checkpoint targets on tumor cells, the majority of which previously had no known function in cancer or immunology, co-founder and CEO Sebastian Meier-Ewert told BioCentury. ...